<DOC>
	<DOCNO>NCT01512797</DOCNO>
	<brief_summary>The purpose study ass whether Januvia ( sitagliptin phosphate 100mg ) safe effective treatment Type 2 Diabetes patient Gastric Bypass .</brief_summary>
	<brief_title>Treatment Diabetes After Gastric Bypass With Sitagliptin</brief_title>
	<detailed_description>Januvia ( sitagliptin phosphate 100mg ) FDA approve medication treatment Type 2 Diabetes . Sitagliptin work inhibit Dipeptidyl peptidase-4 enzyme , result increase active glucagon-like peptide-1 ( GLP-1 ) level . GLP-1 incretin increase post-prandial insulin secretion . Because Gastric Bypass also show increase GLP-1 level , study seek determine additional effect DDP-4 inhibition glucose control patient elevate incretin level post Gastric Bypass . The study also assess Januvia ( Sitagliptin phosphate ) safe well tolerated patient Gastric Bypass . Recruitment data collection study start St. Luke 's Hospital New York , NY later move Columbia University Medical Center New York , NY .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Sitagliptin Phosphate</mesh_term>
	<criteria>Must resident NYC metropolitan area able come emergency unscheduled regular weekly meeting Manhattan . HbA1c ≥ 6.5 % ≤ 8.5 % fast glucose ≥ 126 mg/dL random glucose ≥ 200 mg/dL least 12 month GBP surgery confirm central laboratory . Subject capable willing give inform consent . Subject otherwise good general health , base medical history physical examination . Subject non smoker least 6 month prior study start Female subject child bear potential must use oral , injected implant hormonal method contraception least commencement last normal period prior first administration challenge agent . Subjects use hormonal contraception use barrier method addition first administration challenge agent next normal period follow end study . History type 1 diabetes Female subject pregnant breastfeeding . Recent ( &lt; 30 day ) simultaneous participation another clinical trial . Any situation compromise study , include serious illness predictable lack cooperation subject .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Januvia</keyword>
	<keyword>Sitagliptin</keyword>
	<keyword>Diabetes</keyword>
	<keyword>Gastric-Bypass</keyword>
</DOC>